American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

VACCINEX, INC. (VCNX)

$0.82 +17.20% OTC: VCNX · 15-min delayed

ROCHESTER, New York
Public · OTC: VCNX

Visit website Follow

$601.0KRevenue · FY2024

-$18.6MNet income

VCNXOTC

About VACCINEX, INC.

VACCINEX INC

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Type: Public · OTC: VCNX
Headquarters: ROCHESTER, New York
Industry: Pharmaceuticals
Website: Visit site

Registry IDs

Ticker: VCNX OTC
SEC CIK: 1205922
EIN: 161603202
SIC: 2834 Pharmaceutical Preparations

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show Vaccinex, Inc.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/vaccinex-inc/"><img src="https://americancompanies.com/badge/vaccinex-inc.svg" alt="Vaccinex, Inc. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow VACCINEX, INC. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2024: $601.0K
Net income: -$18.6M
Total assets: $2.6M

Source: SEC EDGAR · updated Jun 8, 2026

OTC: VCNX

$0.82 +17.20%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$0.34 $1.49

52-week range

Open: —
Day range: –
Prev close: —
Volume: —

Vaccinex, Inc. (VCNX) Stock Price

Reported a net loss of $18.6M in FY2024.
Trading 45% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review VACCINEX, INC..

Write a review

Newsroom

News about VACCINEX, INC.

Vaccinex Reports 2025 Annual Financial Results GlobeNewswire Inc. · 2026-04-30 · neutral Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease GlobeNewswire Inc. · 2024-06-06 Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update GlobeNewswire Inc. · 2024-05-15 Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules GlobeNewswire Inc. · 2024-03-27 Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update GlobeNewswire Inc. · 2023-11-13 Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases GlobeNewswire Inc. · 2023-10-26

News & sentiment via Polygon.io

FAQ

Vaccinex, Inc.: frequently asked questions

Is Vaccinex, Inc. an American company?

Vaccinex, Inc. is a US-based company headquartered in Rochester, New York, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Vaccinex, Inc. headquartered?

Vaccinex, Inc. is headquartered in Rochester, New York, United States.

Is Vaccinex, Inc. publicly traded?

Yes — Vaccinex, Inc. is a publicly traded company. Its stock trades under the ticker symbol VCNX on the OTC.

What does Vaccinex, Inc. do?

Vaccinex, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore